About Us

Pioneering Molecular Glues and Protein Degradation Therapies

Who We Are

Progenra is advancing a new class of medicine through Molecular Glues and targeted protein degradation. Our UbiPro™ platform leverages the full power of the ubiquitin system to develop therapies for some of the most challenging diseases.

Vision

To redefine disease treatment through groundbreaking protein degradation science.

Mission

Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system, Molecular Glues and PROTAC drugs, to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas.

UbiPro Platform Highlight

Driven by our powerful and highly productive drug discovery engine, we are delivering a pipeline of first-in-class therapeutics designed to transform the standard of care for patients.

Science that Moves the Field Forward

Our scientific approach is rooted in deep insights into the ubiquitin proteasome system (UPS) and the transformative potential of Molecular Glues and PROTAC technologies. Our strategy combines precision protein degradation with next-generation drug discovery platforms to target complex, previously “undruggable” diseases.

By pushing the boundaries of protein homeostasis research, we aim to deliver first-in-class therapeutics that not only treat, but potentially alter the course of neurodegenerative, cardiovascular, and inflammatory diseases.

Let’s Build the Future of Therapeutics Together

Whether you’re an academic team or biotech investor, we’re ready to explore shared goals.